Related Experiment Video
Updated: Mar 10, 2026

Transurethral Instillation Procedure in Adult Male Mouse
Published on: November 2, 2017
Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study
Fannie Morin1, Anne-Sophie Blais1, Geneviève Nadeau1
1Division of Urology and Regenerative Medicine Axis, Research Center, University Hospital of Quebec-Laval University, Quebec, Quebec, Canada.
Mirabegron as add-on therapy improved bladder capacity and continence in children with refractory overactive bladder. This dual therapy demonstrated good tolerability and safety in this pediatric population.
Area of Science:
- Pediatric Urology
- Pharmacology
- Continence Management
Background:
- Overactive bladder (OAB) in children often requires advanced treatment strategies.
- Antimuscarinics are standard OAB treatments but can have side effects or be ineffective.
- Mirabegron, a beta-3 adrenoreceptor agonist, offers a distinct mechanism of action for OAB.
Purpose of the Study:
- To evaluate the efficacy and safety of mirabegron as an add-on therapy.
- To assess mirabegron's effectiveness in pediatric patients with OAB refractory/intolerant to antimuscarinics.
- To determine if combination therapy improves continence and tolerability.
Main Methods:
- Prospective, off-label study of add-on mirabegron in pediatric patients.
- Efficacy assessed via voiding diaries, post-void residuals, and continence status.
- Safety monitored through urine cultures, ECGs, vital signs, and reported side effects.
Main Results:
- 35 pediatric patients treated for a median of 16.4 months.
- Median bladder capacity increased significantly (50% to 74% expected, p < 0.001).
- All patients showed improved continence, with 12 achieving complete dryness; mild side effects reported in 7.
Conclusions:
- Add-on mirabegron is a safe and effective alternative for pediatric refractory OAB.
- Combination therapy with mirabegron is well-tolerated in children.
- This study represents the first pediatric evaluation of this dual therapy regimen.
Related Concept Videos
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Urinary Tract Calculi III: Medical Management
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Kidney Transplant II: Surgical Procedure
Imaging Studies VI: Voiding Cystourethrography and Cystography

